ici d2138 has been researched along with arachidonic acid in 1 studies
Studies (ici d2138) | Trials (ici d2138) | Recent Studies (post-2010) (ici d2138) | Studies (arachidonic acid) | Trials (arachidonic acid) | Recent Studies (post-2010) (arachidonic acid) |
---|---|---|---|---|---|
23 | 2 | 0 | 19,295 | 486 | 3,040 |
Protein | Taxonomy | ici d2138 (IC50) | arachidonic acid (IC50) |
---|---|---|---|
60 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 4.5 | |
Fatty acid-binding protein, adipocyte | Homo sapiens (human) | 2.75 | |
10 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 4.5 | |
60 kDa chaperonin | Escherichia coli | 7.3 | |
10 kDa chaperonin | Escherichia coli | 7.3 | |
Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.0715 | |
Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.6026 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Crawley, GC; Foster, SJ; McMillan, RM; Spruce, KE; Walker, ER | 1 |
1 other study(ies) available for ici d2138 and arachidonic acid
Article | Year |
---|---|
Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Bronchoconstriction; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Guinea Pigs; Hydroxyurea; Inflammation; Knee Joint; Leukotriene B4; Lipoxygenase Inhibitors; Macrophages; Male; Mice; Oxidation-Reduction; Pyrans; Quinolones; Rabbits; Rats; Thromboxane B2 | 1992 |